SV Health Investors | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/SV Health Investors/Activity

SV Health Investors Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Milestone

Portfolio company Alchemab Therapeutics secured the British Business Bank's largest-ever life sciences investment to advance its AI-enabled antibody pipeline.

Alchemab Therapeutics

Alchemab Therapeutics SV Health Investors

svhealthinvestors.comJUL 9, 2026

JUL 9, 2026

Team Change

Director of Investor Relations Dylan Arpey departed SV Health Investors to lead investor relations and capital formation at Aqualis Partners.

Dylan Arpey departs SV Health

SV Health Investors

briefglance.comMAY 2026

MAY 2026

Investment

Acquired EpiVax, Inc., a bioanalytical CRO specializing in immunogenicity risk assessment, as a new platform investment.

EpiVax

EpiVax SV Health Investors

svhealthinvestors.comAPR 2, 2026

APR 2, 2026

Milestone

Portfolio company Perfuze received FDA clearance for Millipede88, the first super-bore aspiration catheter cleared for standalone direct aspiration.

Perfuze

Perfuze SV Health Investors

svhealthinvestors.comMAR 17, 2026

MAR 17, 2026

Exit

Portfolio company Pivot Point Consulting was acquired by Innovative Consulting Group, forming a unified healthcare IT company.

Pivot Point Consulting

Pivot Point Consulting SV Health Investors

svhealthinvestors.comFEB 17, 2026

FEB 17, 2026

News

Three SV-created biotech companies were named to The Times 100 Tech Ones to Watch list.

The Times 100 Tech Ones to Watch

SV Health Investors

svhealthinvestors.comJAN 16, 2026

JAN 16, 2026

Team Change

Hired Miles Gerson, formerly Head of Takeda Ventures, as Partner to co-lead the Dementia Discovery Funds and expand US investment activity.

Miles Gerson joined as Partner

SV Health Investors

svhealthinvestors.comJAN 9, 2026

JAN 9, 2026

New Fund

The Dementia Discovery Fund closed DDF-2 at $269M, backed by major pharma LPs and nonprofits, to invest in novel dementia therapeutics.

Dementia Discovery Fund 2 (DDF-2)

SV Health Investors

svhealthinvestors.comMAY 20, 2025

MAY 20, 2025